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ABSTRACT: Sequence-dependent thermodynamic quantities for the antiviral agent netropsin and a related

bis(N-methylimidazole) dipeptide, lexitropsin, have been determined by DNase I footprinting techniques.
The primary data are autoradiographic spot intensities derived from 10 footprinting experiments carried
out in the temperature range 0-45 OC. After exclusion effects due to overlapped drug sites on D N A and
redistribution phenomena associated with the enzyme were accounted for, sequence-dependent binding
constants for the two ligands were calculated. Our approach does not require an independent determination
of the free drug concentration, which is calculated, with individual site binding constants, by using only
footprinting data. The temperature dependence of the binding constants for netropsin implied that the binding
enthalpies for all the sites but one on a 139 base pair restriction fragment of pBR 322 D N A are exothermic.
Their values roughly correlate with the free energies of binding, which are smaller for sites including a 5’-TA-3’
sequence. The binding enthalpies for the lexitropsin to all its sites were exothermic and more negative than
those of netropsin. This may be due to the greater ability of the lexitropsin, when compared to netropsin,
to form hydrogen bonds with sites on DNA. The binding constants of the lexitropsin toward its GC interaction
sequences were much lower than those of netropsin, as can be explained by the reduced charge of the former
ligand. Although it is difficult to determine the specific origin of the thermodynamic effects measured,
comparison between netropsin and the lexitropsin suggests that the degree of solvation in the minor groove
of D N A may be a factor influencing the entropy of the binding process.

In

the typical footprinting experiment, a cleavage agent is
used to partially digest a DNA fragment in the presence and
absence of DNA-binding ligand (Galas & Schmitz, 1978;
Schmitz & Galas, 1979; Van Dyke et al., 1982; Lane et al.,
1983; Scamrov & Beabealashvilli, 1983; Fox & Waring,
1984). If the ligand is able to inhibit cleavage at the site of
binding, the locations of these sites appear as omissions or
“footprints” on a DNA sequencing autoradiogram. Aside from
simply revealing the sites of binding, the footprinting experiment has the potential of generating individual site binding
isotherms. This information, which cannot be obtained by any
other experimental technique, allows the determination of
ligand binding constants as a function of sequence on natural
DNA molecules. Ackers and co-workers (Brenowitz et al.,
1986a,b; Senear, et a]., 1986), as well as others (Carey, 1988;
Letovsky & Dynen, 1989), showed that footprinting data could
be used to measure the binding constants of proteins bound
to DNA. Although the low sequence specificity of drugs and
other small ligands leads to complications not found in footprinting experiments involving proteins, it has been demonstrated that quantitative footprinting analysis can be used to
determine the binding constants of the antiviral agent netropsin
(1; Figure 1 ) bound to DNA (Ward et al., 1987, 1988a; Fish
et al., 1988). Additional studies revealed the relationships
between drug-DNA and probe-DNA equilibria and the
manner in which the probe is able to report the occupancy of
a binding site by a drug molecule in the quantitative footprinting experiment (Ward et al., 1988b; Dabrowiak et al.,
1989a,b; Dabrowiak & Goodisman, 1989, 1990; Rehfuss et
al., 1990). In this report we show that it is possible to obtain
a full thermodynamic profile (AGO, A H ” , and A S ” ) of drug
binding as a function of sequence on polymeric DNA by using
only footprinting data.
‘We acknowledge the American Cancer Society, Grant NP-681, for
support of this research.
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The antiviral agent netropsin (1) binds within the minor
groove of DNA to sites of type (AeT),. The specificity of the
agent appears to be related to the fact that the floor of the
minor groove in AT-ri’ch regions of DNA is relatively flat and
featureless (Kopka et al., 1985; Coll et al., 1989). This allows
deep penetration of the drug into the minor groove, producing
close van der Waals contacts and hydrogen bonds between the
agent and DNA. An additional factor influencing specificity
of netropsin is the fact that the minor groove in AT-rich
regions is charged negatively (Lavery & Pullman, 1985).
Since the drug is a dication, electrostatic interactions may also
play a role in the AT specificity of the antiviral agent.
The sequence-reading peptide or lexitropsin (2) was designed
to target GC-rich regions of DNA. Previous footprinting
studies with the compound (Kissinger et al., 1987; Dabrowiak
et al., 1989a) revealed that it exhibits a high affinity for sites
possessing guanine and cytosine in the binding sequence. By
analogy with the single-crystal X-ray analyses of netropsin and
distamycin bound to small segments of DNA (Kopka et al.,
1985; Coll et al., 1989) and from N M R and nuclear Overhauser effect (NOE)’ evidence (Lee et al., 1988), the preference of 2 for GC-rich sites was rationalized in terms of its
ability to accept hydrogen bonds, through the imidazole nitrogens, from the 2-amino group of guanine located in the
minor groove of DNA. This ability, and the ligand’s reduced
cationic charge, are very likely the reasons for enhanced
binding of 2 at GC-rich sites.
MATERIALS
A N D METHODS
Quantitative footprinting studies involving 1 and 2, the latter
a generous gift from J. W. Lown, University of Alberta, were
carried out with DNase I (Ward et al., 1988a). The restriction
fragment, a HindIII/NciI 139 base pair (bp) cleavage product

’ Abbreviations:

NOE, nuclear Overhauser effect; bp, base pairs.
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Structures of netropsin (1) and the sequence reading peptide
lexitropsin (2) and the HindlII/Ncil restriction fragment from
FIGURE 1 :

pBR-322 DNA.

from pBR 322 DNA, was singly end-labeled on its noncoding
strand a t position 33 by using [cv3*P]ATPin the presence of
reverse transcriptase (Lown et al., 1986). The footprinting
experiments were conducted in a total volume of 8 p L in the
buffer 37.5 m M Tris-HC1, 8 m M MgCI2, 2 m M CaCI,, pH
7.5, containing 193 p M bp of sonicated calf thymus DNA,
1 p M labeled fragment, -0.1--0.01
p M DNase I, and
various concentrations of drug. The amount of DNase I
necessary to cleave 20-30% of the labeled fragment (70-80%
uncut) was determined by carrying out a series of calibration
experiments in the absence of drug a t various temperatures.
After electrophoresis in a 12% denaturing polyacrylamide gel
and brief autoradiography to locate the full-length band, the
section of the gel containing the band was excised and subjected to scintillation counting. The amount of cleavage as
determined by counting and also by scanning of the autoradiogram with a microdensitometer was less than -30% (single
hit regime). The footprinting reactions for each ligand were
carried out a t 0, 15, 25, 37, and 45 "C in a buffer medium
containing 37 pM Tris-HCI a t pH 7.5 for 10 min. The reactions for lexitropsin were carried out at the 16 different drug
concentrations shown at the top of Figure 2. While the
netropsin experiments at 0, 15, 25, and 45 "C were carried
out in this study, the data obtained a t 37 "C for the antiviral
agent are those collected and analyzed in an earlier report
(Ward et al., 1988a).
Microdensitometric scanning of the data (Dabrowiak et al.,
1986) showed that the total amount of cleavage on the 139-mer
remained constant as drug was added to the system. After
minor corrections of the density data for gel loading errors,
which were C IO%, plots showing the behavior of the intensity
of each individual band on the autoradiogram as a function
of total drug concentration, termed footprinting plots, were
constructed for each temperature studied. These plots formed
the basis of the analysis (Dabrowiak & Goodisman, 1989,
1 990).
For the calculations on netropsin, we used spot intensities
measured for sites 48, 49, 50-55, 58, 59, 62-67, 83 ,87, 89,
90, 96, 102, and 106 (23 sites). Eight of these were (see below)
enhancement sites; the sites showing drug binding were 48,
50, 51, 53-55, 58, 59, 62, 63, 87, 89, and 90. Intensities for

-

nine drug concentrations in the range 1-10 p M as well as an
experiment at zero drug concentration were used for the digests
at 0, 15, 25, and 45 OC. This gave rise to 230 intensities, which
were used for each temperature. The footprinting analysis a t
37 "C consisted of a slightly larger data set involving 256
intensities (Ward et al., 1988a). In the case of the lexitropsin,
22 sites were monitored: 59, 63, 65-67, 73, 76, 77, 79, 80,
83, 87, 94, 96, 106, 108, 112, 120, 124, 126, 133 and 138,
including 8 for the enhancements. Sites showing drug binding
were as follows: 65-67, 76, 77, 79, 80, 83, 94, 96, 106, 108,
1 12, 120, 124 and 126. Intensities for nine drug concentrations
in the range 0-23 p M were used. This gave rise to 198 intensities used in the minimization.
In order to examine only the earliest loading events on the
restriction fragment and thus minimize any possible drug-drug
cooperativity effects that might be present, only the low drug
concentrations were used in the analysis. The concentrations
employed were determined by noting the level of added drug
for which the strong sites begin to accept ligand, but the weak
sites do not experience binding. In the case of netropsin, this
concentration corresponded to 10 pM drug. For the lexitropsin used in the study, only four distinct regions of inhibition
were observed. Since a clear distinction between their "strong"
and "weak" binding character could not be made, Le., their
respective values of Kiwere more similar in magnitude than
were the "strong" and "weak" binding domains of netropsin,
a decision was made to include concentrations in the range
0-23 pM. Although this allowed access to only the beginning
of the titration curves for the weaker sites, it provided sufficient
data to determine their binding constants. This is because the
footprinting plot, after correction for the mass action effect
associated with DNase I, can be described by a single parameter, the binding constant. Thus, any part of the curve
suffices to determine the binding constant.

-

RESULTS
The footprinting plots showing the cleavage intensity as a
function of drug concentration for either drug were of three
types. Within a binding site DNase I cleavage decreased as
drug was added to the system. This classic footprinting
phenomenon can be seen for lexitropsin (2) at positions 63-72,
76-84, 106-1 14, and 119-127 of Figure 2. At numerous sites
between drug binding sites the cleavage rate was found to
increase as drug was added to the system. For lexitropsin (2),
these increases can be seen a t positions 85-1 IO and a t other
sites on the 139-mer (Figure 2). For certain positions, footprinting plots were observed to increase a t low drug concentration and later, at high drug concentration, decrease. These
positions, associated with secondary drug binding sites, were
not addressed in this study.
DISCUSSION
Model Used To Analyze the Footprinting Data. The general approach for calculating binding constants from footprinting data has been earlier described (Ward et al., 1988a;
Dabrowiak & Goodisman, 1989, 1990). Briefly, the autoradiographic spot intensity for a particular cleavage product is
proportional to the cleavage rate a t the relevant site, (rate),
which is given by expression I . In expression 1, k : is the
(rate)i = k'JDNase 1Ii(1 - vi)
(1)
cleavage rate constant a t the site, [DNase IIi is the effective
concentration of enzyme at the site, and vi is the fraction of
the DNA fragments that have the site blocked by drug. With
increasing drug concentration, vi increases for all sites that can
be blocked by bound drug. Drug binding to certain sites on

Thermodynamic Data from DNA Footprints
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sequence of
FIGURE 2: Results of DNase I footprinting experiments with lexitropsin (2) interacting with the 139-mer at 25 OC. A partial
the noncoding strand of the restriction fragment and position numbers are shown on the left margin of the figure. See Figure 1 for thecomplete
sequence.

a fragment causes an increasing fraction of DNA to be unavailable to the enzyme, making the effective concentration
of DNase I increase at all other DNA sites. Earlier studies
involving netropsin and the intercalating anticancer drug actinomycin D (Ward et al., 1988b) showed that increases in
cleavage are proportional to the amount of DNA blocked by
drug. This mass action effect means a footprinting plot is not
the true isotherm for the site. Thus, the value of [DNase I I i
in expression 1 is taken proportional to (1 - acb)-',where cb
is the concentration of bound drug and CY is a constant describing the enhancement, related to the fraction of sites that
can be blocked by drug from cleavage by DNase I. The value
of a is found along with the drug binding constants in the
minimization (see below).
The relationship between the spot intensity associated with
any oligonucleotide fragment produced in the digest, Ii, taking
into account the mass action effect associated with DNase I,
and the fraction of the site occupied by drug is now given by
(2). In expression 2, ki is a new constant, including k:. In
Ii = ki(l - CYcb)-'(l
- Vi)
(2)

the minimization leading to site-specific binding constants, the
quantity vi is calculated in terms of the relevant drug binding
constant Ki and the free drug concentration cf by use of conventional equilibrium constant expressions. For an isolated
drug binding site
vi

= K i c f / (1

+ K,tf)

(3)

Thefree drug contribution cf is determined from the total drug
concentration by the equilibria between the free drug and the
drug bound to labeled fragment and unlabeled carrier DNA.
Since the carrier concentration (193 pM)is much larger than
that of fragment (1 pM), the equilibrium between the drug
and carrier determines the amounts of free and bound drug
present in the system, and the concentration of fragment need
not be known accurately.
The concentration of strong sites on carrier DNA for lexitropsin (2), c,, can be estimated by noting that there are 4
binding sites for 2 in the 120 base pairs out of a total of 139
observed on the radiolabeled fragment. If the same ratio of
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binding sites to base pairs obtains for the carrier, the concentration of sites on the carrier would be (4/120)(193 y M )
6 yM. Similarly, and considering only the strong sites for
netropsin, a value of about (8/120)(193 y M )
13 y M is
expected for the concentration of strong netropsin sites on the
carrier. In our previous work (Ward et al., 1988a) we incorrectly assumed a strong-site concentration of c, = 194 y M
for netropsin on the carrier DNA. Furthermore, we argued
that the product Kcc,, where K, is the binding constant toward
the carrier DNA, and not the value of c, itself, is important
in determining the amount of drug bound to the carrier. While
this is sometimes true, we now find that K, and c, behave as
independent parameters when c, becomes comparable to or
less than the ligand concentrations used. Thus, the concentration of strong sites on the carrier, c,, and their average
binding constant, K,, can be determined from the footprinting
data derived from the radiolabeled fragment.
The value of K, will be an average of the strong-site binding
constants on the carrier and will also depend on the value
assumed for c, (see below). One cannot directly compare K,
derived from quantitative footprinting analysis with the binding
constant obtained by applying a Scatchard analysis to the
results of optical, filter binding, or phase-partition experiments.
First, as noted by McGhee and Von Hippel (1 974), Scatchard
analysis can give binding constants "substantially in error"
when applied to a substrate possessing overlapping binding
sites. Second, although the binding constant obtained in this
way is, like our K,, a weighted average of binding constants
for different sites, the weighted average in the case of the
Scatchard analysis differs from the weights entering K, derived
from footprinting data, thus complicating the comparison
between the two quantities.
To see what these weights are in the case of the footprinting
data, suppose the actual carrier sites C1, C2, etc. have binding
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constants K,,, Kc2,etc. and concentrations c,, c2, etc., so the
bound-drug concentration, cb, is actually
cb

= CCi KciCf/(I
i

+ Kcjcf)

(4a)

(This assumes carrier sites i do not overlap. If they do, the
equation is somewhat more complicated.) We write instead

For small cf, (4a) becomes
cb =

(CciKci)cf
i
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and (4b) becomes
cb

Table I: Thermodynamic Parameters for Netropsin (1) and
Lexitropsin (2) at 25 OC

= CcKcCf

Thus, K, represents (C,ciKJ/c,, for small drug concentrations.
The equivalence of (4a) and (4b) a t low values of the total
drug concentration is another reason for restricting the analysis
to the earliest parts (low drug) of the footprinting plots.
A third point to make in connection with the values of K,
derived from footprinting data with those obtained through
Scatchard analyses is that in the former case only the earliest
loading events on the carrier are being examined. Typically,
the footprinting-derived values of K, are obtained from data
where the ratio of bound drug to available DNA base pairs,
r, is small <-0.05.
Unfortunately it is this region of the
Scatchard plot, r of <-0.05, where uncertainties are large
and an accurate determination of K from the plot is difficult
to make. Thus, comparisons between K, from footprinting data
and other values obtained through conventional methods may
not be straightforward.
Detrrniination of Binding Constants. After addressing
exclusion effects due to overlapped sites on DNA, the quantities Ii may be calculated for each total ligand concentration,
given values for a, K,, and the Ki. These values are then
determined as those which minimize
D=
- iij)*
(5)
i j

where Iij is the experimental spot intensity for site i, proportional to oligonucleotide concentration, a t a total drug concentration of cj, and iijis the corresponding calculated spot
intensity. The search for values that minimize D is carried
out according to the Simplex search algorithm (Ward et al.,
1988a; Dabrowiak et al., 1989a,b; Dabrowiak & Goodisman,
1989). Direct knowledge of the free drug concentration is not
required: its value for any total drug concentration is calculated in terms of cj and K,. The analysis assumes noncooperative independent binding events on the 139-mer. For the
generally low binding density over the concentration range
studied this assumption is reasonable.
In our first quantitative analysis of a footprinting experiment
(Ward et al., 1988a), we fixed the concentration of strong
netropsin sites on the calf thymus D N A used as a carrier
before minimizing D, the deviation between experimental and
calculated data (eq 5). It is now clear that the value of D
depends on the value assumed for c, (Figure 3). Although
D varies little with c, when the latter quantity is large, there
is a clear minimum for c, of 10 pM for netropsin (Figure
3a). If K , and c, along with the other constants, are determined by minimization of D, the values of the site-specific
binding constants for netropsin toward the fragment are
somewhat lower than those earlier published (Ward et al.,
1988a). As is shown in Figure 3b, the value of c, for the
lexitropsin, as determined by the minimum in D, is 1.4 pM.
Once the values of c, for both ligands were determined a t one
temperature, 37 "C for 1 and 15 "C for 2, this value was fixed
for the remaining minimizations at the various temperatures.
In view of the modest sensitivity of the individual Ki's to the
value of c, (Figure 3), this appears to be a valid approximation.
From analysis of the footprinting experiments at each temperature, we get the binding constants Ki toward the individual
sites on the labeled fragment. These are shown in Figures 4
and 5 as a function of temperature. Linear fits of log Ki versus
1 / T are also shown. From AGO = - R T In K a t 25 "C and
d(log D)/d(l/T) = -AH0/2.303R, we get the thermodynamic
parameters given in Table I. The stated errors in AH" and
AS" come from the correlation coefficients of the least-square
fits. W e also obtain a value for K,, the average binding

-

-

position
46
47
56
57
58
59
89

sequencea
TTTA
AAAT
TTAT
AATA
TTAA
AATT
TAAA
ATTT
AAAT
TTTA
AATT
TTAA
AAAT
TTTA

AGO
AHo
(kJ/mol)
(kJ/mol)
Netropsin (1)
-37.7 f 0.4 -18 f 8

-41.3 f 0.7 -25 f 4

Aso
(J/mol K)
65 f 26
5 4 f 14

25 f 3

195 f IO

-40.7 f 0.7 -22 f 9

62 f 30

-41.9 f 0.8 -16 f 12

87 f 40

-40.6 f 0.6 -10 f IO

102 f 32

-42.6 f 0.3 -12 f 6

103 f 20

-33.1 f 0.6

Lexitropsin (2)b
GCTAACGCAG -26.2 f 0.5 -29.7 f 9.9
-12 f 33
CGATTGCGTC
-46 f 18
76
G G C A C D -30.0 f 0.3 -43.6 f 5.3
CCGTGGCAC
106
CAT-AT
-25.3 f 0.7 -61.4 f 13.0 -121 f 44
GTAGCAGTA
-29.2 f 0.5 -55.9 f 8.7
-89 f 29
119
GGCACCCGTGGCAG
"Sequence is 5'-3' on the coding (top) strand. bSpecific sequences
of ligand contact for 2 are not given. However, the most likely contact
sequence within the entire inhibition region is indicated. The region
was modeled as a single ligand binding event.
63

constant to the strong sites on the carrier D N A (Figure 4).
In the case of netropsin, this value is -1 X IO7 M-I, which
is -2 orders of magnitude higher than those derived by
Scatchard methods (Zimmer & Wahnert, 1986). However,
as was earlier stated, direct comparison between the value of
K, derived from footprinting data and those earlier reported
may not be possible. The value of K, for the lexitropsin was
found to be 6.7 X lo6 M-' a t 25 "C.
Thermodynamic Data. Explaining the thermodynamic data
is made difficult by the fact that contributions to AGO, AH",
and AS" can come from at least three sources (Chaires, 1985).
One includes hydrogen bonding, van der Waals effects, and
hydrophobic/electrostatic interactions between the drug and
its D N A binding site. A second source is conformational
changes that take place within the D N A site or the drug as
binding occurs. Finally, since both the drug and D N A are
highly solvated and have associated counterions, water release
and ion redistribution very likely accompany binding. It is
not possible to unequivocally determine which factor influences
which thermodynamic parameter. However, the reduced
charge of 2 compared to netropsin is probably a major contributing factor to the lower binding constants and less negative
AGO for the former compound (Table I). A parallel argument
can be advanced to explain the lower binding constant of
distamycin, which is a monocation, compared to netropsin,
which is a dication (Zimmer & Wahnert, 1986).
The presence of a 5'-TA-3' sequence in the netropsin binding
site gives rise to a distortion in the minor groove of DNA
(Calladine, 1982). This may not only discourage the binding
of the drug but may also affect the degree of solvation within
the groove (Drew & Dickerson, 1985; Kennard et al., 1986).
Without additional study it is not possible to ascertain the
effects of flanking sequence on the thermodynamic parameters.
However, the sequence 5'-AAAT-3', which occurs imbedded
in an A T tract a t position 58, has essentially the same thermodynamic parameters as does the isolated site of the same
sequence a t 89.
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For netropsin, ASo is positive, as expected for association
of two solvated species, the drug and DNA, with ordered
solvent being released from DNA. Negative values of ASQ
are found for 2, which may reflect the disorderly binding of
water at G C sites (Kennard et al., 1986). This water is liberated from DNA to the more ordered structure of the bulk
solvent.
The values for AHo for netropsin are all negative and about
the same size (from -10 to -25kJ/mol) except for site 56,
having the sequence 5’-TTAA-3’, which is positive. The
earlier, direct, calorimetric measurements of AHo by Breslauer
et al. ( 1988) primarily used poly(dAdT).poly(dAdT), poly(dA).poly(dT) and certain oligonucleotide duplexes as host
DNA for netropsin. The small oligonucleotide duplex, d(GCGAATTCGC)2, studied calorimetrically, possesses the
netropsin binding sequence 5’-AATT-3’, which is found at
position 59 of the 139-mer (Figure I ) . However, despite the
fact that the free energy of netropsin binding to this sequence,
obtained by us (Table I), is similar to that obtained by other
means (Marky & Breslauer, 1987), our enthalpy of -10 f
lOkJ/mol is quite different from that obtained via calorimetric
measurements, -38.9 kJ/mol. It is possible that the restriction
fragment undergoes a structural change over the temperature
range of the study and that this is a factor affecting the
thermodynamic parameters, but this does not appear likely.
DNase I , which is sensitive to DNA structural changes (Drew
& Travers, 1984), showed no change in its cleavage pattern
of the 139-mer as a function of temperature. It is also possible
that the length of DNA is important in the interaction. In
our experiments, the sequence 5’-AATT-3’ is imbedded in a
long polymer, while in the earlier calorimetric studies (Breslauer et al., 1988) it was part of a decamer. Quantitative
footprinting experiments with actinomycin D using a small
DNA oligomer as well as the 139-mer have suggested that
DNA length may affect the binding constant of the anticancer
drug to DNA (Rehfuss et al., 1990; Dabrowiak & Goodisman,
1990). Clearly, additional work involving quantitative footprinting methods and other techniques will be necessary to fully
understand how polymer length, flanking sequences, degree
of solvation, and other factors influence the thermodynamic
properties of drug/DNA interactions at the sequence level.
As is evident from Table I, the errors associated with the
sites for netropsin are quite large. This appears to be due to
the number of overlapped netropsin sites on the 139-mer and
the small (relative to the number of binding constants) number
of concentration points used in the footprinting titrations,
giving rise to fewer data points to fit more parameters. Since
there are no overlaps and fewer parameters to fit, the errors
associated with the lexitropsin are generally lower than those
found for netropsin (Table I).
CONCLUSIONS
In this report we show that, by carrying out multiple
footprinting experiments at a number of different temperatures, it is possible to obtain the full thermodynamic profile
of a drug, AGO, AH’, and ASo, as a function of sequence on
polymeric DNA. The technique requires the measurement
of autoradiographic spot intensities on a DNA sequencing
autoradiogram. With a parametrized model for the various
equilibria present in the system, the difference between calculated and measured intensities is used in a minimization
approach to derive site-specific drug binding constants and
other parameters characterizing the system. The temperature
dependence of the binding constants, given as van’t Hoff plots,
allows the determination of site-specific enthalpies and entropies for the drug. I n the case of netropsin, the enthalpies
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for various sequences on the 139-mer are mostly negative and
agree in size, but are smaller (less negative) than the few
sequence-specific enthalpies determined by other means. The
large negative AHo values observed for the bis(N-methylimidazole) lexitropsin (2) as compared with netropsin may be
due to the greater ability of the former compound to hydrogen
bond to sites located in the minor groove of DNA.
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Preferential Binding of Daunomycin to 5’*CG and 5’tGC Sequences Revealed
by Footprinting Titration Experiments?
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ABSTRACT: Results from a high-resolution deoxyribonuclease I (DNase I) footprinting titration procedure
are described that identify preferred daunomycin binding sites within the 160 bp tyr T D N A fragment.
W e have obtained single-bond resolution a t 65 of the 160 potential binding sites within the tyr T fragment
and have examined the effect of 0-3.0 N M total daunomycin concentration on the susceptibility of these
sites toward digestion by DNase I. Four types of behavior are observed: (i) protection from DNase I cleavage;
(ii) protection, but only after reaching a critical total daunomycin concentration; (iii) enhanced cleavage;
(iv) no effect of added drug. Ten sites were identified as the most strongly protected on the basis of the
magnitude of the reduction of their digestion product band areas in the presence of daunomycin. These
were identified as the preferred daunomycin binding sites. Seven of these 10 sites are found a t the end of
the triplet sequences 5’qGC and 5’iCG, where the notation 4 indicates that either A or T may occup the
position. The remaining three strongly protected sites are found a t the ends of the triplet sequence 5’&$.
Of the preferred daunomycin binding sites we identify in this study, the sequence 5’qCG is consistent with
the specificity predicted by the theoretical studies of Chen et al. [Chen, K.-X., Gresh, N., & Pullman, B.
(1985) J . Biomol. Struct. Dyn. 3, 445-4661 and is the very sequence to which daunomycin is observed to
be bound in two recent X-ray crystallographic studies. Solution studies, theoretical studies, and crystallographic studies have thus converged to provide a consistent and coherent picture of the sequence preference
of this important anticancer antibiotic.

K

T h e cellular target of many clinically useful anticancer
compounds is thought to be DNA (Gale et al., 1981; Chagas
& Pullman, 1987). A necessary step toward the rational
design of new anticancer compounds with enhanced potency
and selectivity is to characterize the DNA binding specificity
of these existing compounds of proven clinical utility and to
elucidate the molecular mechanisms that govern their sequence-selective binding to DNA. It is hoped that this activity
will produce, ultimately, a set of rules to guide the rational
‘Supported by U S .Public Health Service Grant CA35635, awarded
by the National Cancer Institute, Department of Health and Human
Services, National Science Foundation Grant INT-8521004 (J.B.C.), and
grants from the Cancer Research Campaign (M.J.W.).
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design of a new generation of anticancer compounds targeted
to specific DNA sites.
With this larger goal in mind, our laboratory has studied
the interaction of daunomycin with DNA by a variety of
physical and biochemical methods (Britt et al., 1986; Chaires,
1983a,b, 1985a,b; Chaires et al., 1982a,b, 1983, 1985, 1987;
Herrera & Chaires, 1989; Fritzsche et al., 1982, 1987).
Daunomycin is the prototype anthracycline antibiotic, a class
of compounds that has well-documented utility in cancer
chemotherapy (Arcamone, 198 1; Crooke & Reich, 1980;
Remers, 1984). Daunomycin binds to DNA by the process
of intercalation, and the fundamental aspects of the physical
chemistry of its binding to DNA have been well characterized
[for reviews, see Fritzsche and Berg (1987) and Chaires
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